Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access to Novo Nordisk's Wegovy or Eli Lilly's Zepbound, according to the AXIACI ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The ...

Shares in Novo Nordisk, which competes with Eli Lilly (NYSE:LLY) in an obesity drug market that some analysts ... after U.S.

The recent volatility in key GLP-1 stocks has put the spotlight on the anxiety Wall Street has about the weight loss market.

Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with Denmark-based Ascendis Pharma (ASND) to leverage the latter’s advanced ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Novo Nordisk (NVO) and Eli Lilly (LLY) manufacture the top three weight loss drugs on the market, but heightened demand is ...

Shares of Novo Nordisk (NVO) are up 8% in European trading after the Danish pharmaceutical company posted financial results ...

Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound have all become blockbuster drugs, and their momentum ... updates around its three weight loss candidates: AZD5004, AZD6234 ...